Use of Bevacizumab in the Treatment of Corneal Neovascularization

Corneal neovascularization is a serious condition resulting in various degrees of vision loss. The abnormal vascularization blocks the\udlight depending on the corneal scarring, thus it reduces the visual acuity. Corneal neovascularization occurs as a result of shifting the\udbalance between the angiogenic and the antiangiogenic factors on behalf of the angiogenic factors. Vascular endothelial growth factor\ud(VEGF) is the primary mediator of angiogenesis. Anti-VEGF agents are widely used in the treatment of neovascular age-related macular\uddegeneration, diabetic retinopathy, macular edema, neovascular glaucoma, and the other neovascular diseases. These agents are also\udeffective in the treatment of corneal neovascularization. Herein, we discuss the most known anti-VEGF agent bevacizumab and its\udadministration routes, the efficiency and the complications. (Turk J Ophthalmol 2015; 45: 31-36